Abstract
Treatment of chronic hepatitis C (HCV) was based on Interferon alpha IFNa administration three times a week (tiw), but the efficacy of this schedule (evaluated as virological sustained response) was limited to less than 20% of patients. The combination of Ribavirin and IFN is known to be significantly more effective than IFN monotherapy in naive and relapser patients but it induces a sustained response only in 41% of patients and in less than 30% of patients infected with genotype 1. Several studies on IFN and viral kinetics suggested that daily administration of IFN may increase the sustained response rate. The development of pegylated IFNs, characterized by a long half life and weekly administrability, seems to induce a significant improvement in the treatment of chronic hepatitis particularly in combination with Ribavirin. In order to further improve the efficacy of treatment in chronic hepatitis C (HCV) many controlled clinical trials evaluating Amantadine, Micophenolate, a1 Thymosin, Maxamine (in combination with IFN or pegylated IFN), Protease, Helicase, Polymerase inhibitors, Ribozymes and anti-sense olygonucleotides, and Interleukin 10 are in progress. Finally anti-HCV vaccine development seems to be very promising.
Keywords: hepatitis c, ifnx, viral kinetics, hcv, anti-hcv, pegylated interferon
Current Pharmaceutical Design
Title: New Therapies for the Treatment of Chronic Hepatitis C
Volume: 8 Issue: 11
Author(s): G. Ideo and A. Bellobuono
Affiliation:
Keywords: hepatitis c, ifnx, viral kinetics, hcv, anti-hcv, pegylated interferon
Abstract: Treatment of chronic hepatitis C (HCV) was based on Interferon alpha IFNa administration three times a week (tiw), but the efficacy of this schedule (evaluated as virological sustained response) was limited to less than 20% of patients. The combination of Ribavirin and IFN is known to be significantly more effective than IFN monotherapy in naive and relapser patients but it induces a sustained response only in 41% of patients and in less than 30% of patients infected with genotype 1. Several studies on IFN and viral kinetics suggested that daily administration of IFN may increase the sustained response rate. The development of pegylated IFNs, characterized by a long half life and weekly administrability, seems to induce a significant improvement in the treatment of chronic hepatitis particularly in combination with Ribavirin. In order to further improve the efficacy of treatment in chronic hepatitis C (HCV) many controlled clinical trials evaluating Amantadine, Micophenolate, a1 Thymosin, Maxamine (in combination with IFN or pegylated IFN), Protease, Helicase, Polymerase inhibitors, Ribozymes and anti-sense olygonucleotides, and Interleukin 10 are in progress. Finally anti-HCV vaccine development seems to be very promising.
Export Options
About this article
Cite this article as:
Ideo G. and Bellobuono A., New Therapies for the Treatment of Chronic Hepatitis C, Current Pharmaceutical Design 2002; 8 (11) . https://dx.doi.org/10.2174/1381612024607009
DOI https://dx.doi.org/10.2174/1381612024607009 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Searching for Novel Janus Kinase-2 Inhibitors Using a Combination of Pharmacophore Modeling, 3D-QSAR Studies and Virtual Screening
Mini-Reviews in Medicinal Chemistry Intra-Articular Drug Delivery: A Fast Growing Approach
Recent Patents on Drug Delivery & Formulation HIV Pharmacogenetics in Clinical Practice: Recent Achievements and Future Challenges
Current HIV Research Antitumoral Activity of Interferon-γ Involved in Impaired Immune Function in Cancer Patients
Current Drug Metabolism Activin and TGF-β Effects on Brain Development and Neural Stem Cells
CNS & Neurological Disorders - Drug Targets Natural Aldose Reductase Inhibitor: A Potential Therapeutic Agent for Non-alcoholic Fatty Liver Disease
Current Drug Targets Adrenomedullin Expression in Alzheimer's Brain
Current Alzheimer Research The Ovary Feels Fine when Paracrine and Autocrine Networks Cooperate with Gonadotropins in the Regulation of Folliculogenesis
Current Pharmaceutical Design Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research Small Molecule Antagonists of Chemokine Receptors - is Promiscuity a Virtue?
Current Topics in Medicinal Chemistry Mentha L. Species (Lamiaceae) as Promising Sources of Bioactive Secondary Metabolites
Current Pharmaceutical Design The Peripheral Anionic Site of Acetylcholinesterase: Structure, Functions and Potential Role in Rational Drug Design
Current Pharmaceutical Design “Antisurvival” Factor Treatment for Hormone Refractory Prostate Cancer: Secondary Hormonal Ablation Using Somatostatin Analogs
Current Cancer Therapy Reviews Regulatory T Cells in Severe Drug Eruptions
Current Immunology Reviews (Discontinued) Quantum Dot Nanocrystals and Supramolecular Lanthanide Complexes -Energy Transfer Systems for Sensitive In Vitro Diagnostics and High Throughput Screening in Chemical Biology
Current Chemical Biology Review of the Biological Activity of Maslinic Acid
Current Drug Targets NF-κB in Type 1 Diabetes
Inflammation & Allergy - Drug Targets (Discontinued) Is Helicobacter pylori Always a "Bad Guy"?
Current Pharmaceutical Design Patent Selections
Recent Patents on Anti-Infective Drug Discovery Global View on Rare Diseases: A Mini Review
Current Medicinal Chemistry